Some investors may welcome the Novo Nordisk Foundation’s sweeping moves to accelerate a strategy shift. Yet the speed and ...

After losing its leading position in obesity, changing its CEO and triggering a major company reorganization, the pressure is ...

Pharma major CEO Mike Doustdar, on Friday, 31 October 2025, said that the company has notified its employees who have been ...

Novo Nordisk has submitted an unsolicited bid to buy obesity biotech Metsera out from under Pfizer, offering $6 billion ...

Novo Nordisk has made an unsolicited, approximately up to $9 billion bid for Metsera—more than a month after Pfizer announced its intent to buy the company for up to $7.3 billion.

Denmark's Novo Nordisk launched a rival bid for U.S. obesity biotech firm Metsera on Thursday, hijacking an offer from Pfizer as the drugmakers jostled for advantage in the highly lucrative ...

Danish pharma major Novo Nordisk today confirmed that it submitted an unsolicited proposal to acquire Metsera, aiming to ...

Pfizer Inc. today announced that it has filed a lawsuit against Metsera, Inc., its Board of Directors, and Novo Nordisk, S.A. in the Delaware Court of Chancery. The lawsuit asserts claims for breach ...

It was a deal with the Danish drugmaker that markets Ozempic and Wegovy that moved Omeros' stock price. Novo Nordisk ( NVO ...

Omeros' stock surged over 150% after licensing zaltenibart to Novo Nordisk for $240M upfront, plus milestones and royalties. See why OMER is a Buy.

Pfizer is suing over some unsolicited competition in its nearly $5 billion bid to buy the drugmaker Metsera. New York-based Pfizer said Friday after markets closed that it was suing Metsera and ...

LONDON/SAN FRANCISCO (Reuters) -Drugmaker Novo Nordisk has begun a round of layoffs in its most important market, the United States, with affected staff set to be notified between this week and next, ...